Last reviewed · How we verify
NCT07312734: SEND-CF
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
trial in Cystic Fibrosis (CF) in 300 participants. Not yet recruiting.
1 August 2027
Quick facts
| Lead sponsor | Chris Goss |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 February 2026 |
| Primary completion | 1 August 2027 |
| Estimated completion | 1 August 2027 |
| Sites | 9 locations across United States |
Conditions studied
- Cystic Fibrosis (CF) — all drugs for Cystic Fibrosis (CF) →
- New Diagnostics — all drugs for New Diagnostics →
Sponsor
Chris Goss — full company profile →
Who can join
16 and older, any sex, with Cystic Fibrosis (CF) or New Diagnostics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07312734
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cystic Fibrosis (CF)
Currently open trials in the same condition.
- NCT07303621 — Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population · recruiting
- NCT07071324 — CF Wellness Program · NA · recruiting
- NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
- NCT07363304 — Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People Wi · recruiting
- NCT07508904 — Exercises' Effect on Muscle Strength, Aerobic Capacity and Respiratory Functions in Cystic Fibrosis · NA · recruiting
Other Chris Goss trials
Trials by the same sponsor.
- NCT05548283 — Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study · Phase 4 · recruiting
- NCT05285410 — Observational Study Comparing Home to Office Spirometry · completed
- NCT04294043 — IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study) · Phase 1 · recruiting
- NCT03801993 — Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07312734 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chris Goss
- Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07312734.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing